Section Arrow
SPRB.NASDAQ
- Spruce Biosciences Inc
Quotes are at least 15-min delayed:2026/11/04 14:31 EST
Regular Hours
Last
 45.24
+2.43 (+5.68%)
Day High 
46.14 
Prev. Close
42.81 
1-M High
49.85 
Volume 
34.65K 
Bid
44.73
Ask
45.34
Day Low
44.43 
Open
44.43 
1-M Low
38.06 
Market Cap 
123.04M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 45.11 
20-SMA 43.5 
50-SMA 49.55 
52-W High 129 
52-W Low 38.06 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-38.43/-14.32
Enterprise Value
123.46M
Balance Sheet
Book Value Per Share
29.13
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CRISCuris Inc.1.2301+0.5162+72.31%0.2PE
KPTIKaryopharm Therapeutics Inc.0.0852-0.0031-3.51%-- 
GERNGeron Corp1.035+0.105+11.29%-- 
INOInovio Pharmaceuticals1.655-0.005-0.30%-- 
NRIXNurix Therapeutics16.31-9.51-36.83%10.63PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.